What is Cibinetide (ARA-290)?

The short answer

Cibinetide, or ARA-290, is a lab-made peptide based on part of the body's red blood cell hormone.

3 sources
Status as of October 4, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialUpdated October 12, 2026AI use

Get updates on Cibinetide (ARA-290)

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: Cibinetide (ARA-290) (1 selected) · edit

Peptides you're interested inCibinetide (ARA-290)

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on Cibinetide (ARA-290)

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: EPO-derived peptide

Regulatory status

Not FDA-approved How we label status

As of October 4, 2026, Cibinetide (ARA-290) is not FDA-approved for any use and is not on FDA's 503A bulks list.

See Cibinetide (ARA-290) in the Index →

Federal (FDA): Not FDA-approved
503A compounding: Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026)

Timeline

Scroll sideways to see all columns.

Date	What happened	Source
May 14, 2026	FDA list of bulk drug substances nominated under section 503A, updated May 14, 2026, places cibinetide (ARA-290) in category 3, nominated without adequate support.	FDA, event of May 14, 2026, on fda.gov

References

Sources as of October 4, 2026